OncLive TV

Amrita Krishnan, MD, highlights key innovations in multiple myeloma, including GPRC5D-targeted agents and evolving strategies in T-cell–directed therapy.

Syed Abbas Ali, MBBS, discusses treatment decisions for patients with R/R myeloma for whom CAR T-cell therapy and bispecific antibodies are both options.

Oleg Gluz, MD, discusses findings from subgroup analyses of the WSG-TP-II trial of neoadjuvant de-escalated chemotherapy in HER2-positive breast cancer.

R. Lor Randall, MD, FACS, discusses the application of a bioengineered bone marrow matrix as a three-dimensional model to analyze osteosarcoma cell behavior under varying oxygen tensions.

Jeffrey Zonder, MD, discusses the need for increased awareness in multiple myeloma.

Shilpa Gupta, MD, discusses OS outcomes with first-line maintenance avelumab plus BSC in advanced urothelial carcinoma based on diabetes mellitus.

Hyun-Woong Cho, MD, PhD, discusses the efficacy of maintenance therapy with niraparib plus bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Zamtocabtagene autoleucel was associated with a manageable safety profile with no grade 3 or higher CRS and low ICANS rates in relapsed/refractory DLBCL.

Alan H. Bryce, MD, discusses treatment comparisons of ARPI efficacy according to disease volume and timing of metastasis development in mHSPC.

Timothy S. Fenske, MD, MS, discusses survival outcomes in patients with MCL who remained MRD positive following consolidative auto-HCT.

Sheela Rao, MBBS, MD, FRCP, highlights the current treatment landscape in the localized anal cancer setting for anal cancer Awareness Day, March 21.

Yufei Liu, MD, PhD, discusses SBRT and IMRT strategies and the role of radiation in patients with colorectal cancer.

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

R. Lor Randall, MD, FACS, discusses how to select between vimseltinib, pexidartinib, and surgery for patients with tenosynovial giant cell tumor.

Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.

Alfred L. Garfall, MD, describes the inclusion criteria for a phase 2 study evaluating ide-cel as first-line maintenance in multiple myeloma.

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Marwan Fakih, MD, discusses the advancement of botensilimab/balstilimab–based combination therapies in microsatellite-stable colorectal cancer.

Alberto Montero, MD, MBA, CPHQ, explains the rationale for evaluating zanidatamab plus evorpacept in HER2-expressing metastatic breast cancer.

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.

Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.

Melanie A. Sheen, MD, discusses a study aimed at determining differences in breast composition and assess racial disparities in access to and utilization of genetic counseling.

Amanda Herrmann, MD, discusses findings from the TIME-TOX Lung study, which retrospectively assessed the time toxicity associated with lung cancer clinical trials.

Raajit Rampal, MD, discusses the variety of agents in phase 3 trials for the treatment of patients with myelofibrosis.

Shannon Westin, MD, MPH, FACOG, discusses the efficacy of durvalumab plus chemotherapy and olaparib in pMMR recurrent endometrial cancer.

Jordyn Silverstein, MD, discusses the efficacy of abemaciclib plus hormonal therapy in recurrent ovarian cancer or endometroid endometrial cancer.

Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.

Joshua Richter, MD, discusses the evolution of multiple myeloma treatment in recognition of Myeloma Awareness Month 2025.